MedTrace Logo

LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC

NCT06531902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2024-08-01

No results posted yet for this study

Summary

The current study will compare the blood expression level of lncRNA NNT-AS1 and hsa-miR-485-5p, as well as heat shock protein 90 (HSP90) serum levels in both healthy and CRC Egyptian patients' cohort peripheral blood samples. Second, examine if lncRNA NNT-AS1/hsa-miR-485 5p/HSP90 axis, or individually investigated, would be used as a non-invasive molecular precision biomarker in liquid biopsy for better diagnostic utility for CRC patients. Also, based on CRC patients' group stratification by histologic grades 1-3. Finally, investigate the probable link/correlation between lncRNA NNT-AS1/hsa-miR-485-5p/HSP90 as an axis or individually in CRC Egyptian patients' cohort in relation to demographic data or clinicopathological characteristics. All findings will be confirmed or ruled out by in silico means as well.

Conditions

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nadia Hamdy, PhD · Faculty of pharmacy Ain Shams University

Eligibility

Min Age
24 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-03-01
Completion
2021-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531902 on ClinicalTrials.gov